Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by eyeNteeon May 06, 2015 3:05am
117 Views
Post# 23698313

Clinical research into PTSD

Clinical research into PTSDAlso new on VPT's website is Upcoming research on how patients with Post Traumatic Stress Disorder have a link to heart disease or heart falure and how VMS will be used to help them.                                                                                                                                                                              

Planning the Future

One of the most difficult tasks in cardiac care is identifying HF before an individual becomes symptomatic and presents to the hospital for the first time. This is where Ventripoint, through the use of its VMS™, is able to add great value to any future PTSD and HF studies. Current available data allows for quantification of multiple cardiac parameters via 2D Echocardiography (Echo), Electrocardiogram (EKG/ECG), and results derived from blood analysis. The widest used cardiac imaging method used to date for assessment of HF is 2D Echo, due to the fact it is relatively inexpensive and readily available, especially compared to cardiac MRI (cMRI), which is considered the Gold Standard for cardiac chamber quantification. In determining heart failure, it is imperative to be able to determine the efficiency, or Ejection Fraction (EF) of the Left and Right Ventricle (LV and RV), as well as the volumes for each, namely the End Diastolic (ED) volume. Current routine Echo includes the parameters of the LV including EF and volumes. Although commercial technology is available to assess the RV EF and volumes, due to the challenges presented by the RV, namely the complex geometry, results vary greatly between methods. Only the VMS™ provides results of RV EF and volumes that have been determined by the FDA to be substantially equivalent to the Gold Standard cMRI. It is hypothesized that the key to better understanding the causative link between PTSD and HF, and improving diagnosis and outcomes of HF, lies within a better understanding of the RV functional parameters. 

As indicated by the referenced literature, potential pathways by which HF may occur with PTSD is related to dysregulation of hormones that cause inflammation of vascular endothelium. This includes the vascular structure of the lungs, which can directly and adversely affect the RV volumes leading to subsequent failure of both the RV and LV. 

It is therefore recommended that any future research conducted to evaluate individuals with PTSD should be mandated to include accurate quantification of the volume and function of the RV. As such, the VMS™ would provide the most accurate and cost effective method for providing this information. 
Bullboard Posts